Seikagaku reported FY 1Q21 orthopedic revenue of USD $33.3 million, +14.4% vs. FY 1Q20. Marketshare gains in the U.S. and China drove the growth, while domestic sales in Japan decreased due to pricing reductions and ordering patterns.
In June 2021, Seikagaku issued a Dear Healthcare Professionals Letter of Rapid Safety Communication (Blue Letter) in response to “multiple reports of shock or anaphylaxis occurring in patients following administration of JOYCLU.” That product is a 30mg Intra-articular Injection, a joint function improvement agent, for which Seikagaku received manufacturing and marketing approval in Japan in 1Q21. The company and its partner Ono Pharmaceutical continue gathering information on side effects.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
1Q21
1Q20
$ Chg
% Chg
Orthobiologics
$33.3
$29.1
$4.2
14.4%
Geographic Sales
1Q21
1Q20
$ Chg
% Chg
Domestic (Japan)
$16.6
$17.0
($0.4)
(2.4%)
International
$16.6
$12.1
$4.6
38%
Total
$33.3
$29.1
$4.2
14.4%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 1Q21 orthopedic revenue of USD $33.3 million, +14.4% vs. FY 1Q20. Marketshare gains in the U.S. and China drove the growth, while domestic sales in Japan decreased due to pricing reductions and ordering patterns.
In June 2021, Seikagaku issued a Dear Healthcare Professionals Letter of Rapid Safety Communication (Blue...
Seikagaku reported FY 1Q21 orthopedic revenue of USD $33.3 million, +14.4% vs. FY 1Q20. Marketshare gains in the U.S. and China drove the growth, while domestic sales in Japan decreased due to pricing reductions and ordering patterns.
In June 2021, Seikagaku issued a Dear Healthcare Professionals Letter of Rapid Safety Communication (Blue Letter) in response to “multiple reports of shock or anaphylaxis occurring in patients following administration of JOYCLU.” That product is a 30mg Intra-articular Injection, a joint function improvement agent, for which Seikagaku received manufacturing and marketing approval in Japan in 1Q21. The company and its partner Ono Pharmaceutical continue gathering information on side effects.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
1Q21
1Q20
$ Chg
% Chg
Orthobiologics
$33.3
$29.1
$4.2
14.4%
Geographic Sales
1Q21
1Q20
$ Chg
% Chg
Domestic (Japan)
$16.6
$17.0
($0.4)
(2.4%)
International
$16.6
$12.1
$4.6
38%
Total
$33.3
$29.1
$4.2
14.4%
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
